Abstract
Simple SummaryNon-small cell lung cancer (NSCLC) is the most common malignancy requiring radiotherapy (RT) as an important part of its multimodality treatment, the emergence of proton therapy may further allow for a sharper dose of build-up and drop-off com-pared to photon therapy, which has potentially improved clinical outcomes of NSCLC. Currently, there has been much emerging evidence focusing on dosimetry, efficacy, safety, and cost-effectiveness of proton therapy for non-small cell lung cancer (NSCLC) published, however, a comprehensive review comparing these therapies is, to date, lacking. This review focuses on these aspects of dosimetry, efficacy, safety, and cost-effectiveness of proton therapy for NSCLC.Non-small cell lung cancer (NSCLC) is the most common malignancy which requires radiotherapy (RT) as an important part of its multimodality treatment. With the advent of the novel irradiation technique, the clinical outcome of NSCLC patients who receive RT has been dramatically improved. The emergence of proton therapy, which allows for a sharper dose of build-up and drop-off compared to photon therapy, has potentially improved clinical outcomes of NSCLC. Dosimetry studies have indicated that proton therapy can significantly reduce the doses for normal organs, especially the lung, heart, and esophagus while maintaining similar robust target volume coverage in both early and advanced NSCLC compared with photon therapy. However, to date, most studies have been single-arm and concluded no significant changes in the efficacy for early-stage NSCLC by proton therapy over stereotactic body radiation therapy (SBRT). The results of proton therapy for advanced NSCLC in these studies were promising, with improved clinical outcomes and reduced toxicities compared with historical photon therapy data. However, these studies were also mainly single-arm and lacked a direct comparison between the two therapies. Currently, there is much emerging evidence focusing on dosimetry, efficacy, safety, and cost-effectiveness of proton therapy for NSCLC that has been published, however, a comprehensive review comparing these therapies is, to date, lacking. Thus, this review focuses on these aspects of proton therapy for NSCLC.
Highlights
Lung cancer is the most commonly diagnosed malignancy and cause of cancer-related death, and patients affected by non-small cell lung cancer (NSCLC) comprise > 80% of the patients with lung cancer [1]
3-dimensional conformal radiation therapy (3D-CRT), intensity-modulated RT (IMRT), and volumetric-modulated arc therapy (VMAT), the clinical outcome has dramatically improved with modern RT compared to conventional RT [2,3]
This review summarized the published studies involving these aspects of proton therapy for NSCLC
Summary
Lung cancer is the most commonly diagnosed malignancy and cause of cancer-related death, and patients affected by non-small cell lung cancer (NSCLC) comprise > 80% of the patients with lung cancer [1]. Proton therapy is one of the types of RT that uses charged particles, allowing for a sharp dose build-up and drop-off compared to conventional photon therapy, which may further improve dose conformity, reducing damage to the surrounding normal tissue [3,5,6,7]. Emerging published studies have outlined the efficacy of proton therapy for NSCLC with a focus on dosimetry, efficacy, safety, and cost-effectiveness, a comprehensive review is lacking. This review summarized the published studies involving these aspects of proton therapy for NSCLC. Studies were published between 1 April 1972 and 30 June 2021. Studies within these parameters that focused on dosimetry, efficacy, and safety, and cost-effectiveness were classified and included
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
